OBJECTIVES: Cervical cancer is the leading gynecological malignancy worldwide, and the incidence of this disease is very high in American Indian women. Infection with the human papillomavirus (HPV) is responsible for more than 95% of cervical squamous carcinomas. Therefore, the main objective of this study was to analyze oncogenic HPV infections in American Indian women residing in the Northern Plains. METHODS: Cervical samples were collected from 287 women attending a Northern Plains American Indian reservation outpatient clinic. DNA was extracted from the cervical samples and HPV-specific DNA was amplified by polymerase chain reaction (PCR) using the L1 consensus primer sets. The PCR products were hybridized with the Roche HPV Line Blot assay for HPV genotyping to detect 27 different low- and high-risk HPV genotypes. The Chi-squared test was performed for statistical analysis of the HPV infection and cytology diagnosis data. RESULTS: Of the total 287 patients, 61 women (21.25%) tested positive for HPV infection. Among all HPV-positive women, 41 (67.2%) were infected with high-risk HPV types. Of the HPV infected women, 41% presented with multiple HPV genotypes. Additionally, of the women infected with oncogenic HPV types, 20 (48.7%) were infected with HPV16 and 18 and the remaining 21 (51.3%) were infected with other oncogenic types (i.e., HPV59, 39, 73). Women infected with oncogenic HPV types had significantly higher (p=0.001) abnormal Papanicolaou smear tests (Pap test) compared to women who were either HPV negative or positive for non-oncogenic HPV types. The incidence of HPV infection was inversely correlated (p<0.05) with the age of the patients, but there was no correlation (p=0.33) with seasonal variation. CONCLUSIONS: In this study, we observed a high prevalence of HPV infection in American Indian women residing on Northern Plains Reservations. In addition, a significant proportion of the oncogenic HPV infections were other than HPV16 and 18.
OBJECTIVES: Cervical cancer is the leading gynecological malignancy worldwide, and the incidence of this disease is very high in American Indian women. Infection with the human papillomavirus (HPV) is responsible for more than 95% of cervical squamous carcinomas. Therefore, the main objective of this study was to analyze oncogenic HPV infections in American Indian women residing in the Northern Plains. METHODS: Cervical samples were collected from 287 women attending a Northern Plains American Indian reservation outpatient clinic. DNA was extracted from the cervical samples and HPV-specific DNA was amplified by polymerase chain reaction (PCR) using the L1 consensus primer sets. The PCR products were hybridized with the Roche HPV Line Blot assay for HPV genotyping to detect 27 different low- and high-risk HPV genotypes. The Chi-squared test was performed for statistical analysis of the HPV infection and cytology diagnosis data. RESULTS: Of the total 287 patients, 61 women (21.25%) tested positive for HPV infection. Among all HPV-positive women, 41 (67.2%) were infected with high-risk HPV types. Of the HPV infectedwomen, 41% presented with multiple HPV genotypes. Additionally, of the women infected with oncogenic HPV types, 20 (48.7%) were infected with HPV16 and 18 and the remaining 21 (51.3%) were infected with other oncogenic types (i.e., HPV59, 39, 73). Women infected with oncogenic HPV types had significantly higher (p=0.001) abnormal Papanicolaou smear tests (Pap test) compared to women who were either HPV negative or positive for non-oncogenic HPV types. The incidence of HPV infection was inversely correlated (p<0.05) with the age of the patients, but there was no correlation (p=0.33) with seasonal variation. CONCLUSIONS: In this study, we observed a high prevalence of HPV infection in American Indian women residing on Northern Plains Reservations. In addition, a significant proportion of the oncogenic HPV infections were other than HPV16 and 18.
Authors: William J M Hrushesky; Robert B Sothern; Wop J Rietveld; Jovelyn Du-Quiton; Mathilde E Boon Journal: Int J Biometeorol Date: 2005-10-06 Impact factor: 3.787
Authors: P E Castle; S L Hillier; L K Rabe; A Hildesheim; R Herrero; M C Bratti; M E Sherman; R D Burk; A C Rodriguez; M Alfaro; M L Hutchinson; J Morales; M Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-10 Impact factor: 4.254
Authors: Philip E Castle; Tammy Shields; Reinhard Kirnbauer; M Michele Manos; Robert D Burk; Andrew G Glass; Daivid R Scott; Mark E Sherman; Mark Schiffman Journal: Sex Transm Dis Date: 2002-03 Impact factor: 2.830
Authors: Charles V Biscotti; Dawn L O'Brien; Margaret A Gero; Terry L Gramlich; Alexander W Kennedy; Kirk A Easley Journal: J Reprod Med Date: 2002-01 Impact factor: 0.142
Authors: K Iihara; H Shiozaki; H Tahara; K Kobayashi; M Inoue; S Tamura; M Miyata; H Oka; Y Doki; T Mori Journal: Cancer Date: 1993-05-15 Impact factor: 6.860
Authors: Grace A Alfonsi; S Deblina Datta; Theresa Mickiewicz; Laura A Koutsky; Khalil Ghanem; Michael Hagensee; Peter Kerndt; Katherine Hsu; Hillard Weinstock; Judith C Shlay Journal: Public Health Rep Date: 2011 May-Jun Impact factor: 2.792
Authors: Maria C Bell; Delf Schmidt-Grimminger; Clemma Jacobsen; Subhash C Chauhan; Diane M Maher; Dedra S Buchwald Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482
Authors: Isabel C Scarinci; Francisco A R Garcia; Erin Kobetz; Edward E Partridge; Heather M Brandt; Maria C Bell; Mark Dignan; Grace X Ma; Jane L Daye; Philip E Castle Journal: Cancer Date: 2010-06-01 Impact factor: 6.860